InNexus Biotechnology Performance
| IXSBFDelisted Stock | USD 0.0001 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and InNexus Biotechnology are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days InNexus Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, InNexus Biotechnology is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
InNexus |
InNexus Biotechnology Relative Risk vs. Return Landscape
If you would invest 0.01 in InNexus Biotechnology on September 26, 2025 and sell it today you would earn a total of 0.00 from holding InNexus Biotechnology or generate 0.0% return on investment over 90 days. InNexus Biotechnology is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded stocks are less volatile than InNexus, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
InNexus Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InNexus Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as InNexus Biotechnology, and traders can use it to determine the average amount a InNexus Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IXSBF |
Based on monthly moving average InNexus Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InNexus Biotechnology by adding InNexus Biotechnology to a well-diversified portfolio.
InNexus Biotechnology Fundamentals Growth
InNexus Stock prices reflect investors' perceptions of the future prospects and financial health of InNexus Biotechnology, and InNexus Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InNexus Stock performance.
| Return On Asset | -0.31 | |||
| Current Valuation | 6.69 M | |||
| Shares Outstanding | 163.2 M | |||
| Price To Sales | 17.10 X | |||
| EBITDA | (1.37 M) | |||
| Cash And Equivalents | 31.43 K | |||
| Total Debt | 3.36 M | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (1.59 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 3.44 M | |||
| Retained Earnings | (33.15 M) | |||
About InNexus Biotechnology Performance
By analyzing InNexus Biotechnology's fundamental ratios, stakeholders can gain valuable insights into InNexus Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if InNexus Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if InNexus Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking technology. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada. Innexus Biotechnology is traded on OTC Exchange in the United States.Things to note about InNexus Biotechnology performance evaluation
Checking the ongoing alerts about InNexus Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InNexus Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InNexus Biotechnology is not yet fully synchronised with the market data | |
| InNexus Biotechnology generated a negative expected return over the last 90 days | |
| InNexus Biotechnology has some characteristics of a very speculative penny stock | |
| InNexus Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (6.69 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| InNexus Biotechnology has accumulated about 31.43 K in cash with (1.59 M) of positive cash flow from operations. |
- Analyzing InNexus Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InNexus Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining InNexus Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InNexus Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of InNexus Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InNexus Biotechnology's stock. These opinions can provide insight into InNexus Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in InNexus Stock
If you are still planning to invest in InNexus Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InNexus Biotechnology's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |